Search

Displaying results 2581 - 2590 of 7018 in total
  1. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    medium that is then processed and purified for use as a pharmaceutical agent. … It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX.

  2. Drug

    Norethynodrel

    go.drugbank.com/drugs/DB09371
    Approved

    As a contraceptive, it has usually been administered in combination with MESTRANOL. … A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis.

  3. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  4. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    It may have some anticonvulsant properties.

  5. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver. … [L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher.

  6. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    D-Serine

    go.drugbank.com/drugs/DB03929
    ApprovedInvestigationalWithdrawn

    A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.

  8. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.

  10. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib]. … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal